Lux Research Launches China BioPharma Service, Expands Broader Life Sciences ...
Comprising a talented team of well-networked, native analysts based in Shanghai, Singapore and Boston, the service will provide Lux Research’s global clients with ongoing technology scouting and market intelligence from one of the world’s fastest-growing biopharmaceutical markets and the world’s most dynamic economy.
“China Rising is an apt description of the entry and presence of China on the world biopharmaceutical stage. China has made biotechnology and healthcare a major funding prerogative in its long-term R&D strategy,” said Kevin Pang, Lux Research Director. “With the 2009-2011 period seeing a cumulative CNY2.6 billion (US$411 million) invested across 223 projects, China’s spending on basic research funding has risen 30-fold over the past 15 years.”
The China BioPharma Intelligence service will cover the broad landscape of emerging innovative technologies and companies, delivering keen insights into market dynamics and trends, while cutting through the complex regulatory and government-driven environment. It will provide regular, detailed guidance on a wide variety of drug and device development technologies ranging from stem cells to molecular diagnostics and sensors, medical devices, genomics and proteomics, novel formulation and therapeutics.
![[News]](http://nt3.ggpht.com/news/tbn/VwKrGMdWJJcfWM/6.jpg)
Crigler also oversees Orkin's international franchises' digital marketing and infrastructure and supports Rollins' other brands, including Western Pest Services, PCO Services, Trutech and Waltham Services Inc. with their interactive strategy and
After a full decade of horror, the turnaround shocked the baseball world, but how did they do it? Jonah Keri's The Extra 2% is a combo baseball and business book, but it's not a how-to about how to run a baseball team or a business.
